TP53 and cardiovascular disorder: This association may stem from multiple factors, including higher genomic instability in tumors of elderly patients (e.g., mutations in RB1 and TP53)33,34, reduced tolerance to chemotherapy due to comorbidities (e.g., cardiovascular diseases) and lower frequency of monitoring for musculoskeletal symptoms leading to diagnostic delays35,36.